BBIO News and Press, BridgeBio Pharma Inc. From 03/06/23

2023-03-06 13:05:55 ET Gainers: Bellerophon ( BLPH ) +86% . Ambrx Biopharma ( AMAM ) +69% . BridgeBio Pharma ( BBIO ) +56% . Avalon GloboCare ( ALBT ) +47% . Azul ( AZUL ) +42% . TCR2 Therapeutics ( TCRR ) +38% . ...

2023-03-06 13:03:55 ET The following slide deck was published by BridgeBio Pharma, Inc. in conjunction with this event. For further details see: bridgebio shares phase 2 data for infigratinib in achondroplasia

2023-03-06 12:22:36 ET Shares of BridgeBio Pharma (NASDAQ: BBIO) were skyrocketing 61.2% higher as of 11:55 a.m. ET on Monday. The huge gain came after the company announced positive results from a patient cohort in a phase 2 clinical study evaluating infigratinib in treating childr...

2023-03-06 10:00:19 ET Gainers: BridgeBio Pharma ( BBIO ) +67% . Armata Pharmaceuticals ( ARMP ) +23% . TCR2 Therapeutics ( TCRR ) +21% . Euda Health ( EUDA ) +12% . Kala Pharmaceuticals ( KALA ) +16% . Losers: Aclaris...

2023-03-06 08:21:43 ET BridgeBio Pharma ( NASDAQ: BBIO ) jumped ~55% pre-market Monday after announcing Phase 2 data for infigratinib, which is an investigational therapy for children with achondroplasia, the most common cause of disproportionate short stature. Cohort 5,...

- In the highest dose level (Cohort 5, 0.25 mg/kg once daily), the mean change from baseline in annualized height velocity (AHV) at six months was +3.03 cm/yr (p = 0.0022 ) for the first 10 children with at least six months of follow-up in Cohort 5. The two remaining children who have not yet...

PALO ALTO, Calif., March 03, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of its management team will host an investor call on Monday, March 6 at 7:30 ...

The following slide deck was published by BridgeBio Pharma, Inc. in conjunction with their 2023 Q1 earnings call. For further details see: BridgeBio Pharma, Inc. 2023 Q1 - Results - Earnings Call Presentation

BridgeBio Pharma press release ( NASDAQ: BBIO ): Q4 GAAP EPS of -$0.92 misses by $0.07 . Revenue of $1.87M (-85.5% Y/Y) misses by $3.05M . Cash, cash equivalents, marketable securities and restricted cash (current), totaled $466.2 million as of December 31, 2022, ...

–Phase 3 ATTRibute-CM registrational trial of acoramidis for transthyretin amyloid cardiomyopathy (ATTR-CM) continues to have high operating fidelity; month 30 topline registrational data are expected to be announced in mid-2023 –Phase 2 PROPEL 2 trial of low-dose infigrat...